ASSOCIATION OF THE TP53 PIN3 16-BP DUPLICATION POLYMORPHISM WITH ORAL SQUAMOUS CELL CARCINOMA RISK AND PROGNOSIS
Abstract
Background/Aim: Oral squamous cell carcinoma (OSCC) is associated with multiple risk factors, including genetic variations such as the TP53 PIN3 16-bp duplication polymorphism. This study aimed to assess the association between this polymorphism and susceptibility to OSCC in the Montenegrin population and to evaluate its influence on OSCC prognosis and progression.
Materials and Methods: Genomic DNA extracted from 60 patients with OSCC and 71 cancer-free controls was analyzed using the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) technique to identify TP53 PIN3 genotypes and allele frequencies. Clinical and pathological data, along with three-year follow-up outcomes, were also analyzed.
Results: During the follow-up period, 12 patients (20%) experienced local recurrence of disease and 6 patients (10%) developed regional metastases, with no distant metastases detected. No significant associations were observed between the PIN3 16-bp duplication polymorphism and patient age, tumor site, grade, disease recurrence, or metastasis (p > 0.05). A significant association between TP53 genotypes and advanced stage of disease was found (p = 0.006). There were no significant differences in disease-free survival among genotypes: A1A1 (28.26 ± 1.70 months), A1A2 (35.00 ± 0.94 months), and A2A2 (30.00 ± 5.20 months) (p = 0.38). Additionally, no significant differences in allele or genotype frequencies between patients and controls were observed (p > 0.05).
Conclusion. The TP53 PIN3 16-bp duplication polymorphism cannot be considered a risk factor for OSCC development in the Montenegrin population. Furthermore, this polymorphism does not modulate susceptibility to OSCC progression.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal, A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209–249. doi: 10.3322/caac.21660.
Williams HK. Molecular pathogenesis of oral squamous cell carcinoma. Mol Pathol. 2000; 53(4):165-72. doi: 10.1136/mp.53.4.165.
SharmaS, Sambyal V, Guleria K, Manjari M, Sudan M, Uppal MS et al. TP53 polymorphisms in sporadic North Indian breast cancer patients. Asian Pac J Cancer Prev. 2014; 15(16):6871-9. doi: 10.7314/apjcp.2014.15.16.6871.
Gavrić I, Hodžić E, Sarajlić L, Salibašić M, Bajramagić S, Dizdarević A, et al. Analysis of TP53, APC, KRAS, and MMR genetic mutations in colorectal cancer: a review article. Sanamed. 2024; 19(3): 333-41. doi: 10.5937/sanamed0-52803.
Diakité B, Kassogue Y, Dolo G, Kassogue O, Keita ML, Joyce B et al. Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis. BMC Med Genet. 2020: 21(1):142. doi: 10.1186/s12881-020-01072-4.
Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene.2004; 23(10):1954-6.doi: 10.1038/sj.onc.1207305.
Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010; 31(4):643-7. doi: 10.1093/carcin/bgq018.
Bišof V, Peričić Salihović M, Smolej Narančić N, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, et al. The TP53 gene polymorphisms and survival of sporadic breast cancer patients. Med Oncol. 2012; 29(2):472-8.doi: 10.1007/s12032-011-9875-2.
Gallì P, Cadoni G, Volante M, Feo ED, Amore R, Giorgio A et al. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer.2009; 9:137. doi: 10.1186/1471-2407-9-137
Neves Filho EH, Cordeiro DE, Vieira AP, Rabenhorst SH. TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis. Pathobiology. 2012; 79(6):323-8. doi: 10.1159/000338436.
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis. 2013; 4(2):e492.doi: 10.1038/cddis.2013.24.
Malik MA, Sharma K, Goel S, Zargar SA, Mittal B. Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley. Oncol Res.2011; 19(3-4):165-9. doi: 10.3727/096504011x12935427587920.
Pouladi N, Kouhsari SM, Feizi MH, Dehghan R, Azarfam P, Farajzadeh D. Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev.2014; 15(6):2631-4.doi: 10.7314/apjcp.2014.15.6.2631.
HaoW, Xu X, Shi H, Zhang C, Chen X. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation. Eur J Med Res. 2018; 23(1):47.doi: 10.1186/s40001-018-0345-6.
Marouf C, Tazzite A, Diakité B, Jouhadi H, Benider A, Nadifi S. Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population. Tumour Biol. 2014; 35(12):12403-8.doi: 10.1007/s13277-014-2556-y.
Hashemi M, Amininia S, Ebrahimi M, Simforoosh N, Basiri A, Mohsen Ziaee SA et al. Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett. 2017; 13(4):2483–9. doi: 10.3892/ol.2017.5739.
MortenBC, Chiu S, Oldmeadow C, Lubinski J, Scott RJ, Avery-Kiejda KA . The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer. Breast Cancer Res Treat. 2019; 173(3):727-33. doi: 10.1007/s10549-018-5039-9.
Patel KR, Vajaria BN, Begum R, Shah FD, Patel JB, Shukla SN, et al. Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, West India. Asian Pac J Cancer Prev. 2013; 14(2):1093-100.doi: 10.7314/apjcp.2013.14.2.1093.
Antunović M. Prognostic significance of the correlation between p53, survivin and human papillomavirus type 16 (HPV-16) in oral carcinoma [PhD Dissertation].[Podgorica]: Faculty of Medicine, University of Montenegro; 2014. 50 p. Available from: https://phaidra.ucg.ac.me/detail_object/o:668
Copyright (c) 2026 Sanamed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Sanamed is published under an Open Access license. All its content is available free of charge. Users can read, download, copy, distribute, print, search the full text of articles, as well as establish HTML links to them, without having to seek the consent of the author or publisher.
The right to use content without consent does not release the users from the obligation to give the credit to the journal and its content in a manner described under CC BY.